This Plan has been co-financed by the Ministry of Science and Innovation with funds from the European Union NextGenerationEU (PRTR-C17.I1).
NEWSLETTER REGISTRATION:
In recent years, relevant biotechnological and digital developments (artificial intelligence, supercomputing, robotics and sensor technology, bioengineering, or nanotechnology, among others) have been achieved that are enabling the generation and massive analysis of omic data related to health and disease. This is leading to a radical change in the tools for designing and producing new diagnostic, prognostic and therapeutic systems and devices.
The integration and adoption of these enabling technologies in the biotechnology and medical technology industry is where the great potential lies for achieving personalized or precision medicine that establishes, for each individual, tools for prevention according to their predisposition to certain diseases, systems for early diagnosis, and methods for choosing the therapeutic strategy that best suits each person in each circumstance.
However, only with an integrative approach that takes into account the great complexity of human pathologies will we be able to respond to the most important health challenges we face: cancer, diseases associated with the aging process, minority diseases and infectious diseases.
Increase knowledge of the effects of all possible variants in human and pathogen genomes, transcriptomes, proteomes.
To deepen the study of gene expression at the individual cellular level, essential to develop new advanced diagnostic and prognostic systems and to identify new therapeutic targets.
To develop new personalized and targeted therapies such as nanodrugs, as well as advanced surgical techniques through the development of preclinical disease models that exploit the potential of biomimetic systems and biomodels.
Como parte de los esfuerzos de internacionalización, Valentín Ceña, coordinador científico del Plan Complementario de Biotecnología en Castilla-La Mancha, ha
Investigadores del Plan Complementario de Biotecnología en Galicia, País Vasco y Cataluña hablaron de farmacología, biología estructural y resistencia de
El proyecto AKRIBEA se centra en desarrollar una plataforma de recopilación y procesamiento de datos obtenidos de una cohorte de
Un proyecto liderado por Andalucía busca desarrollar herramientas biotecnológicas y bioinformáticas con el objetivo de definir el perfil molecular de
Siguiendo con nuestro objetivo de acercar la ciencia a la sociedad, el Plan Complementario, en colaboración con el Instituto de
La acción colaborativa DATOS-CAT tiene como objetivo potenciar la visibilidad y el impacto científico de las cohortes de base poblacional
El Plan Complementario Biotecnología Aplicada a la Salud, integrado en el marco del PERTE para la Salud de Vanguardia, ha sido cofinanciado por el Ministerio de Ciencia, Innovación y Universidades con fondos de la Unión Europea NextGenerationEU, el Plan de Recuperación, Transformación y Resiliencia (PRTR-C17.I1) y las siguientes comunidades autónomas:
